Using loratadine to reduce bone pain from G-CSF in multiple myeloma patients during stem cell mobilization

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This early phase I trial investigates the effectiveness of loratadine, an antihistamine, in alleviating bone pain caused by granulocyte-colony stimulating factor (G-CSF) in patients with multiple myeloma undergoing stem cell mobilization. Participants are randomly assigned to receive either loratadine or a placebo starting five days before G-CSF treatment and continuing until five days after stem cell collection. The study aims to evaluate the efficacy of loratadine and assess the need for additional pain relief medications. Additionally, it seeks to identify risk factors for developing G-CSF induced bone pain.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient must be able to provide informed consent
* Patients with confirmed diagnosis of multiple myeloma
* Able to swallow and retain oral medication
* All ethnic groups are eligible

Exclusion Criteria:

* Non-English speaking person
* Patients undergoing haploidentical allogeneic hematopoietic stem cell transplant
* Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
* Any medical complications or conditions that would, in the investigator's judgement, interfere with full participation in the study
* On therapeutic dose of aspirin (doses greater than 81 mg) within 7 days prior to the start of the study

Where it's running

• Rutgers Cancer Institute of New Jersey
  New Brunswick, New Jersey, United States Recruiting
• RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick
  New Brunswick, New Jersey, United States Not yet recruiting

Study contacts

• Principal investigator: Mansi R. Shah, MD — Rutgers Cancer Institute of New Jersey
• Study coordinator: Mansi R. Shah, MD
• Email: shahmr@cinj.rutgers.edu
• Phone: 732-235-4439

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Imaging for detecting cancer cells in multiple myeloma

  This study is testing a new imaging agent to see if it can better detect cancer cells in people with multiple myeloma compared to standard imaging methods.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT05892393

• Comparing drug combinations for treating newly diagnosed multiple myeloma in patients not suitable for stem cell transplant

  This study is testing different combinations of three drugs to see which works best for people with newly diagnosed multiple myeloma who can't have a stem cell transplant.

  Recruiting at 388 sites Phase 3 SWOG Cancer Research Network · Anchorage, Alaska and 396 other locations · NCT05561387

• Improving quality of life and immune function in multiple myeloma patients through lifestyle changes

  This study is testing whether lifestyle changes like exercise and diet can improve the immune system and quality of life for people with multiple myeloma.

  Recruiting Roswell Park Cancer Institute · Buffalo, New York · NCT05312255

• Combination treatment for high-risk myeloma using belantamab mafodotin, pomalidomide, and dexamethasone

  This study is testing a new combination of three medications to see if it can help people with high-risk plasma cell myeloma feel better and improve their treatment outcomes.

  Recruiting Phase 2 Emory University · Atlanta, Georgia · NCT05208307

• Assessing cognitive effects of whole brain radiation therapy in blood cancer patients

  This study is testing how whole brain radiation therapy affects thinking and memory in blood cancer patients, while also looking at quality of life and brain changes over time.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT05011045

• Combining four drugs to treat newly diagnosed multiple myeloma

  This study is testing if adding a fourth drug to a three-drug treatment helps adults with newly diagnosed multiple myeloma live longer and feel better.

  Recruiting at 303 sites Phase 3 Eastern Cooperative Oncology Group · Anchorage, Alaska and 646 other locations · NCT04566328

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.